Paul Sekhri - Ipsen SA Independent Director
| IPN Stock | EUR 109.50 1.90 1.71% |
Insider
Paul Sekhri is Independent Director of Ipsen SA since 2018.
| Age | 61 |
| Tenure | 6 years |
| Phone | 33 1 58 33 50 00 |
| Web | https://www.ipsen.com |
Paul Sekhri Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Sekhri against Ipsen SA stock is an integral part of due diligence when investing in Ipsen SA. Paul Sekhri insider activity provides valuable insight into whether Ipsen SA is net buyers or sellers over its current business cycle. Note, Ipsen SA insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ipsen SA'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Sekhri over three months ago Disposition of 290 shares by Paul Sekhri of Veeva Systems subject to Rule 16b-3 |
Ipsen SA Management Efficiency
The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Guillaume Bouhours | Biomerieux SA | 47 | |
| Isabelle Posth | SEB SA | N/A | |
| Stanislas Gramont | SEB SA | 57 | |
| Mark Miller | Biomerieux SA | N/A | |
| Pierre Charbonnier | Biomerieux SA | N/A | |
| Delphine Vaylet | SEB SA | 53 | |
| Valerie Hanote | Eurofins Scientific SE | 57 | |
| Petra Kirchhoff | Sartorius Stedim Biotech | 54 | |
| Joachim Reichelt | Eurofins Scientific SE | N/A | |
| Cyril Buxtorf | SEB SA | 57 | |
| Alexandre Merieux | Biomerieux SA | 49 | |
| David Bryant | Eurofins Scientific SE | N/A | |
| Pierre Boulud | Biomerieux SA | 52 | |
| Olivier Guitard | Sartorius Stedim Biotech | N/A | |
| Philippe Sumeire | SEB SA | 61 | |
| Benedikt Orzelek | Sartorius Stedim Biotech | N/A | |
| MariePierre Chevallier | Arkema SA | 64 | |
| Timothy Oostdyk | Eurofins Scientific SE | N/A | |
| Philippe Schaillee | SEB SA | N/A | |
| Giles Pelissier | SEB SA | N/A | |
| Laurent Lebras | Eurofins Scientific SE | N/A | |
Management Performance
Ipsen SA Leadership Team
Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Garidel, Chairman, CEO and Chairman of Strategic Committee | ||
| Paul Sekhri, Independent Director | ||
| Henri Beaufour, Director | ||
| Gwenan White, Executive Vice President Communications and Public Affairs | ||
| Francois Garnier, Executive Vice President General Counsel, Member of the Executive Committee | ||
| Carol Xueref, Independent Director | ||
| Richard Paulson, Executive Vice President and Chief Executive Officer of Ipsen North America | ||
| Dominique Bery, Executive Vice President, Strategy and Transformation | ||
| Yan Moore, Senior Vice President Head of Oncology Therapeutics Area | ||
| Aidan Murphy, Executive Vice-President Technical Operations | ||
| Piet Wigerinck, Independent Director | ||
| David Loew, Chief Executive Officer, Director | ||
| Margaret Liu, Independent Director | ||
| Craig Marks, VicePres Relations | ||
| Howard Mayer, Executive Vice President, Head of Research & Development | ||
| Yan MD, VP Area | ||
| Regis Mulot, Chief Human Resource Officer, Executive Vice President | ||
| Alexander McEwan, Vice President and Head of Radiopharmaceuticals | ||
| Ivana MagovcevicLiebisch, Executive Vice President Chief Business Officer | ||
| Philippe Bonhomme, Director, Permanent representative of Beech Tree SA | ||
| Michele Ollier, Independent Director | ||
| Carol Stuckley, Independent Director | ||
| JeanMarc Parant, Director, representing Employees | ||
| Steven Hildemann, Executive Vice President Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance | ||
| Harout Semerjian, Executive Vice President & President Specialty Care International & Global Franchises | ||
| Anne Beaufour, Director, Permanent representative of Highrock S.àr.l. | ||
| Philippe LopesFernandes, Executive Vice President Chief Business Officer | ||
| Aymeric Chatelier, Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President | ||
| Benoit Hennion, Executive Vice President and President Consumer Helathcare | ||
| Dominique Laymand, Executive Vice President, Chief Ethics and Compliance Officer | ||
| Antoine Flochel, Vice Chairman of the Board | ||
| Stephan Gagne, Head Office |
Ipsen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 8.46 B | |||
| Shares Outstanding | 82.63 M | |||
| Shares Owned By Insiders | 57.12 % | |||
| Shares Owned By Institutions | 20.19 % | |||
| Price To Earning | 13.13 X | |||
| Price To Book | 2.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ipsen Stock
Ipsen SA financial ratios help investors to determine whether Ipsen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ipsen with respect to the benefits of owning Ipsen SA security.